Johnson & Johnson

142.49-0.7800-0.54%Vol 5.70M1Y Perf 0.81%
Jul 9th, 2020 16:00 DELAYED
BID141.65 ASK142.92
Open142.76 Previous Close143.27
Pre-Market142.95 After-Market142.77
 -0.32 -0.22%  0.28 0.20%
Target Price
165.31 
Analyst Rating
Moderate Buy 1.56
Potential %
16.02 
Finscreener Ranking
★★+     48.00
Insiders Trans % 3/6/12 mo.
-/-50/-43 
Value Ranking
★★+     49.77
Insiders Value % 3/6/12 mo.
-/-99/-94 
Growth Ranking
★★★★     60.47
Insiders Shares Cnt. % 3/6/12 mo.
-/-99/-93 
Income Ranking
★★+     47.26
Market Cap375.40B 
Earnings Rating
Sell
Price Range Ratio 52W %
69.67 
Earnings Date
16th Jul 2020

Today's Price Range

140.58144.42

52W Range

109.16157.00

5 Year PE Ratio Range

14.30310.40

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
1.63%
1 Month
-1.84%
3 Months
1.44%
6 Months
-1.46%
1 Year
0.81%
3 Years
8.10%
5 Years
47.80%
10 Years
182.35%

TickerPriceChg.Chg.%
JNJ142.49-0.7800-0.54
AAPL382.731.36000.36
GOOG1 510.9914.99001.00
MSFT214.321.49000.70
XOM41.36-1.7800-4.13
WFC24.04-0.5100-2.08
FB244.500.92000.38
GE6.58-0.2800-4.08
JPM91.28-2.0200-2.17
Financial StrengthValueIndustryS&P 500US Markets
1.00
1.30
0.29
0.45
81.60
Leverage Ratio 2.60
ProfitabilityValueIndustryS&P 500US Markets
66.20
23.80
32.20
24.20
18.59
RevenueValueIndustryS&P 500US Markets
62.17B
23.58
1.00
2.16
DividendsValueIndustryS&P 500US Markets
2.83
4.04
5.22
14.31
Payout ratio66.00
Earnings HistoryEstimateReportedSurprise %
Q01 20202.032.3013.30
Q04 20191.861.881.08
Q03 20192.002.126.00
Q02 20192.422.586.61
Q01 20192.032.103.45
Q04 20181.951.971.03
Q03 20182.032.050.99
Q02 20182.062.101.94
Earnings Per EndEstimateRevision %Trend
6/2020 QR1.45-23.68Negative
9/2020 QR2.03-13.62Negative
12/2020 FY7.68-10.28Negative
12/2021 FY9.12-3.59Negative
Next Report Date16th Jul 2020
Estimated EPS Next Report1.46
Estimates Count7
EPS Growth Next 5 Years %6.00
Volume Overview
Volume5.70M
Shares Outstanding2.63B
Trades Count65.51K
Dollar Volume1.02B
Avg. Volume9.40M
Avg. Weekly Volume5.48M
Avg. Monthly Volume7.26M
Avg. Quarterly Volume7.99M

Johnson & Johnson (NYSE: JNJ) stock closed at 143.27 per share at the end of the most recent trading day (a 0.29% change compared to the prior day closing price) with a volume of 6.26M shares and market capitalization of 375.40B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 135100 people. Johnson & Johnson CEO is Alex Gorsky.

The one-year performance of Johnson & Johnson stock is 0.81%, while year-to-date (YTD) performance is -1.78%. JNJ stock has a five-year performance of 47.8%. Its 52-week range is between 109.16 and 157, which gives JNJ stock a 52-week price range ratio of 69.67%

Johnson & Johnson currently has a PE ratio of 22.30, a price-to-book (PB) ratio of 6.15, a price-to-sale (PS) ratio of 6.06, a price to cashflow ratio of 16.50, a PEG ratio of 2.32, a ROA of 11.25%, a ROC of 19.29% and a ROE of 28.55%. The company’s profit margin is 18.59%, its EBITDA margin is 32.20%, and its revenue ttm is $62.17 Billion , which makes it $23.58 revenue per share.

Of the last four earnings reports from Johnson & Johnson, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.46 for the next earnings report. Johnson & Johnson’s next earnings report date is 16th Jul 2020.

The consensus rating of Wall Street analysts for Johnson & Johnson is Moderate Buy (1.56), with a target price of $165.31, which is +16.02% compared to the current price. The earnings rating for Johnson & Johnson stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Johnson & Johnson has a dividend yield of 2.83% with a dividend per share of $4.04 and a payout ratio of 66.00%.

Johnson & Johnson has a Buy technical analysis rating based on Technical Indicators (ADX : 11.83, ATR14 : 2.71, CCI20 : 22.22, Chaikin Money Flow : -0.08, MACD : -0.97, Money Flow Index : 58.55, ROC : -0.08, RSI : 50.87, STOCH (14,3) : 70.54, STOCH RSI : 1.00, UO : 61.52, Williams %R : -29.46), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Johnson & Johnson in the last 12-months were: Alex Gorsky (Option Excercise at a value of $0), Ashley McEvoy (Option Excercise at a value of $0), Hubert Joly (Buy at a value of $706 399), Jennifer L. Taubert (Option Excercise at a value of $0), Joaquin Duato (Option Excercise at a value of $0), Joseph J. Wolk (Option Excercise at a value of $0), Kathryn E. Wengel (Option Excercise at a value of $126 305), Kathryn E. Wengel (Sold 2 017 shares of value $284 538 ), Kathy Wengel (Option Excercise at a value of $126 305), Kathy Wengel (Sold 2 017 shares of value $284 538 ), Michael E. Sneed (Option Excercise at a value of $3 639 975), Michael E. Sneed (Sold 58 128 shares of value $8 683 568 ), Michael H. Ullmann (Option Excercise at a value of $0), Michael Sneed (Option Excercise at a value of $3 639 975), Michael Sneed (Sold 58 128 shares of value $8 683 568 ), Paulus Stoffels (Option Excercise at a value of $0), Peter M. Fasolo (Option Excercise at a value of $0), Robert J. Decker (Option Excercise at a value of $0), Thibaut Mongon (Option Excercise at a value of $1 738 618), Thibaut Mongon (Sold 39 224 shares of value $5 803 583 ), William D. Perez (Buy at a value of $63 843)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (68.75 %)
11 (68.75 %)
10 (66.67 %)
Moderate Buy
1 (6.25 %)
1 (6.25 %)
1 (6.67 %)
Hold
4 (25.00 %)
4 (25.00 %)
4 (26.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.56
Moderate Buy
1.56
Moderate Buy
1.60

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, close to half of total revenue is generated in the United States.

CEO: Alex Gorsky

Teplephone: +1 732 524-0400

Address: One Johnson & Johnson Plaza, New Brunswick 08933, NJ, USA

Number of employees: 135 100

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

49%51%

Bearish Bullish

50%50%

News

Stocktwits